Cargando…

The data management of a phase III efficacy trial of an 11-valent pneumococcal conjugate vaccine and related satellite studies conducted in the Philippines

BACKGROUND: A large phase III placebo-controlled, randomized efficacy trial of an investigational 11-valent pneumococcal conjugate vaccine against pneumonia in children less than 2 years of age was conducted in the Philippines from July 2000 to December 2004. Clinical data from 12,194 children who w...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sanvictores, Diozele Hazel M, Lucero, Marilla G, Nohynek, Hanna, Tallo, Veronica L, Tanskanen, Antti, Nillos, Leilani T, Williams, Gail
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2012
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3434041/ https://www.ncbi.nlm.nih.gov/pubmed/22676626 http://dx.doi.org/10.1186/1756-0500-5-274

Ejemplares similares

Geographic Information System and tools of spatial analysis in a pneumococcal vaccine trial
por: Tanskanen, Antti, et al.
Publicado: (2012)

Capture-recapture analysis of all-cause mortality data in Bohol, Philippines
por: Carter, Karen L, et al.
Publicado: (2011)

Safety and immunogenicity of three doses of an eleven-valent diphtheria toxoid and tetanus protein – conjugated pneumococcal vaccine in Filipino infants
por: Capeding, Maria Z Rosario, et al.
Publicado: (2003)

Assessing the quality of medical death certification: a case study of concordance between national statistics and results from a medical record review in a regional hospital in the Philippines
por: Lucero, Marilla, et al.
Publicado: (2018)

Poor Growth and Pneumonia Seasonality in Infants in the Philippines: Cohort and Time Series Studies
por: Paynter, Stuart, et al.
Publicado: (2013)

Population-based otoscopic and audiometric assessment of a birth cohort recruited for a pneumococcal vaccine trial 15–18 years earlier: a protocol
por: Chan, Kenny, et al.
Publicado: (2021)

Using Mathematical Transmission Modelling to Investigate Drivers of Respiratory Syncytial Virus Seasonality in Children in the Philippines
por: Paynter, Stuart, et al.
Publicado: (2014)

National Influenza Surveillance in the Philippines from 2006 to 2012: seasonality and circulating strains
por: Lucero, Marilla G., et al.
Publicado: (2016)

Impact of Ten-Valent Pneumococcal Conjugate Vaccination on Invasive Pneumococcal Disease in Finnish Children – A Population-Based Study
por: Jokinen, Jukka, et al.
Publicado: (2015)

Impact of ten-valent pneumococcal conjugate vaccine on pneumonia in Finnish children in a nation-wide population-based study
por: Palmu, Arto A., et al.
Publicado: (2017)

On the estimation of population cause-specific mortality fractions from in-hospital deaths
por: Williams, Gail M., et al.
Publicado: (2019)

Indirect effect of 7-valent and 13-valent pneumococcal conjugated vaccines on pneumococcal pneumonia hospitalizations in elderly
por: Kislaya, Irina, et al.
Publicado: (2019)

Invasive Pneumococcal Disease and 7-Valent Pneumococcal Conjugate Vaccine, the Netherlands
por: van Deursen, Anna M.M., et al.
Publicado: (2012)

Health and economic outcomes of 20-valent pneumococcal conjugate vaccine compared to 15-valent pneumococcal conjugate vaccine strategies for adults in Greece
por: Gourzoulidis, George, et al.
Publicado: (2023)

Impacts of the 13-Valent Pneumococcal Conjugate Vaccine in Children
por: Esposito, Susanna, et al.
Publicado: (2015)

Predictors to parental knowledge about childhood immunisation/EPI vaccines in two health districts in Cameroon prior to the introduction of 13-valent Pneumococcal Conjugate Vaccines (PCV-13)
por: Libwea, John Njuma, et al.
Publicado: (2014)

Effectiveness of the 13-Valent Pneumococcal Conjugate Vaccine on Invasive Pneumococcal Disease in Greenland
por: Nikolova, Kristiana Alexandrova, et al.
Publicado: (2021)

The impact of introduction of the 10-valent pneumococcal conjugate vaccine on pneumococcal carriage in Nigeria
por: Adamu, Aishatu L., et al.
Publicado: (2023)

Cost-effectiveness of a national immunization program with the 13-valent pneumococcal conjugate vaccine compared with the 10-valent pneumococcal conjugate vaccine in South Korea
por: Kim, Hye-Young, et al.
Publicado: (2020)

Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine compared to the 23-valent pneumococcal polysaccharide vaccine in elderly Japanese adults
por: Shiramoto, Masanari, et al.
Publicado: (2015)

Invasive pneumococcal infection despite 7-valent conjugated vaccine
por: Joye, Sebastien, et al.
Publicado: (2013)

Cost-effectiveness of 13-valent pneumococcal conjugate vaccination in Mongolia
por: Sundaram, Neisha, et al.
Publicado: (2017)

Efficacy and Safety of the Pneumococcal Conjugate-13 Valent Vaccine in Adults
por: Marra, Fawziah, et al.
Publicado: (2019)

Higher valent Pneumococcal Conjugate Vaccines: is it a roller coaster?
por: Oligbu, Godwin
Publicado: (2020)

Decrease in Pneumococcal Co-Colonization following Vaccination with the Seven-Valent Pneumococcal Conjugate Vaccine
por: Valente, Carina, et al.
Publicado: (2012)

Direct Effect of 10-Valent Conjugate Pneumococcal Vaccination on Pneumococcal Carriage in Children Brazil
por: Andrade, Ana Lucia, et al.
Publicado: (2014)

A Review of the Impact of Pneumococcal Polysaccharide Conjugate Vaccine (7-valent) on Pneumococcal Meningitis
por: Tin Tin Htar , Myint, et al.
Publicado: (2013)

1430. Evolving Impact of 13-Valent Pneumococcal Conjugate Vaccine on Invasive Pneumococcal Disease
por: Yildirim, Inci, et al.
Publicado: (2018)

Cost-effectiveness analysis of replacing the 10-valent pneumococcal conjugate vaccine (PCV10) with the 13-valent pneumococcal conjugate vaccine (PCV13) in Brazil infants
por: Perdrizet, Johnna, et al.
Publicado: (2020)

Estimating the Public Health and Economic Impact of Introducing the 13-Valent Pneumococcal Conjugate Vaccine or 10-Valent Pneumococcal Conjugate Vaccines into State Immunization Programs in India
por: Ghia, Canna J., et al.
Publicado: (2021)

Serotype Replacement after Introduction of 10-Valent and 13-Valent Pneumococcal Conjugate Vaccines in 10 Countries, Europe
por: Hanquet, Germaine, et al.
Publicado: (2022)

Estimating the Clinical and Economic Impact of Switching from the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) to the 10-Valent Pneumococcal Conjugate Vaccine (PCV10) in Italy
por: Ansaldi, Filippo, et al.
Publicado: (2020)

Correction to: Estimating the Public Health and Economic Impact of Introducing the 13-Valent Pneumococcal Conjugate Vaccine or 10-Valent Pneumococcal Conjugate Vaccines into State Immunization Programs in India
por: Ghia, Canna J., et al.
Publicado: (2021)

Cost-effectiveness of 2 + 1 dosing of 13-valent and 10-valent pneumococcal conjugate vaccines in Canada
por: Earnshaw, Stephanie R, et al.
Publicado: (2012)

Pneumococcal Infection among Children before Introduction of 13-Valent Pneumococcal Conjugate Vaccine, Cambodia
por: Turner, Paul, et al.
Publicado: (2015)

647 Impact of 13-valent Pneumococcal Conjugate Vaccine on Invasive Pneumococcal Disease in the United States
por: Kim, Lindsay, et al.
Publicado: (2014)

Evolution of pneumococcal serotype epidemiology in Botswana following introduction of 13-valent pneumococcal conjugate vaccine
por: Patel, Sweta M., et al.
Publicado: (2022)

1738. Cost-Effectiveness Analysis of Infant Pneumococcal Vaccination with the 20-Valent Pneumococcal Conjugate in the US
por: Rozenbaum, Mark, et al.
Publicado: (2023)

Poor Potential Coverage for 7-Valent Pneumococcal Conjugate Vaccine, Malawi
por: Gordon, Stephen B., et al.
Publicado: (2003)

Impact of the 7-valent pneumococcal conjugate vaccine on the incidence of childhood pneumonia
por: ELEMRAID, M. A., et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_j4ed1mo9bdttamc6fpl6r8fj43